Washington Research Foundation
Facts
- HQ
- Washington State
- Sectors
- Non-profit Organizations
- Founded
- 1981
- Employees
- 22
- Founders
- Tom Cable, Bill Gates, Sr., Hunter Simpson
2Morrow raises $1.5M led by WRF Capital, total funding now $2.9M to expand ACT-based digital therapeutics
Seattle-area digital therapeutics startup 2Morrow raised $1.5 million, bringing total funding to $2.9 million, to expand its smartphone-based coaching apps that use Acceptance and Commitment Therapy for smoking cessation, weight loss, stress and grief. The 11-person company, led by CEO and co-founder Jo Masterson, saw increased demand in 2020 and has partnered with Fred Hutchinson Cancer Research Center since 2013.
Rad Power Bikes co-founder Ty Collins steps down to advisory role; WRF CEO Ron Howell to retire end of April
Rad Power Bikes co-founder and former CMO Ty Collins has stepped down and moved into an advisory role while remaining involved; the company is profitable and raised $150 million earlier this year. Washington Research Foundation CEO Ron Howell will retire at the end of April after 29 years, with CFO Jeff Eby serving as acting CEO.
Athira Pharma raises $204M in IPO at $17/share, values company at ~$670M to advance Alzheimer’s drug NDX-1017
Seattle biotech Athira Pharma raised $204 million by selling 12 million shares in a Nasdaq IPO at $17 per share, valuing the company at about $670 million as it advances its lead Alzheimer’s therapeutic NDX-1017 into late-stage development.
Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS
Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.
Seattle’s A-Alpha Bio Raises $2.8M Seed Round to Advance AlphaSeq Drug Discovery Platform
Seattle startup A-Alpha Bio raised $2.8 million in seed funding to advance its genetically engineered protein analysis platform, AlphaSeq, which accelerates drug candidate evaluation by sorting millions of protein interactions. The round was led by OS Fund and included investors such as Madrona Venture Group and AME Cloud Ventures.
Seattle Startup Nexgenia Raises $2M to Broaden Polymer Reagent Technology for Immunotherapy Applications
Seattle biotech startup Nexgenia, led by CEO Ron Myers, raised $2 million to expand its polymer-based reagents for sorting cells in immunotherapy production to new applications. The funding, led by the W Fund and Washington Research Foundation, will support further research into diverse uses of their technology beyond cancer treatment.
People
-
William Canestaro Managing Director
